Roberts David B, President and Director, has demonstrated a clear selling bias in recent transactions involving LeMaitre Vascular (LMAT), with $1.26 million in total sales since late February 2026. The most significant disposals occurred on February 27, 2026 ($903,957.74) and March 11, 2026 ($356,585.81), accounting for the bulk of his recent activity. These sales contrast sharply with his historical buying pattern, which totals $503,047.80 across 45 transactions—though no purchases have been recorded in the most recent filings. The transactions include a mix of sales (code S), acquisitions via derivative securities (code A), and transactions involving minor tax-related adjustments (codes F and M), though the latter categories represent negligible dollar values compared to the outright sales.
Roberts’ trading activity has been exclusively concentrated in LMAT, with no recent transactions in other companies. The absence of any buys in 2026, combined with the two high-value sales, suggests a shift toward reducing his position. While earlier filings show smaller transactions—including tax withholdings and derivative adjustments—the recent disposals stand out in both size and timing. The lack of new acquisitions during this period reinforces the trend toward divestment rather than accumulation. All figures are based on SEC Form 4 disclosures, with no indication of whether these sales represent routine portfolio management or other considerations.
AI-assisted summary